This site uses cookies to improve your experience.

We use necessary cookies to make our site work. We would also like to set optional analytics cookies to help us improve our site by anonymously collecting and reporting information on how you use it. For more information on how these cookies work, please see our Cookie policy.

Vision Fund investment portfolio company Neuron23's logo

Neuron23 is using data and genomics to create precision medicines that fight debilitating diseases.

Leadership
Nancy StaglianoPhD
Fund
SVF2
Status
Private
Sector
Health Tech
Region
Americas
Insights
Roundup
Data and ML are creating a golden age of drug discovery

The biotech sector is poised to reap the benefits of the AI revolution, with lifesaving effects

Q&A
Nancy Stagliano: Bringing AI to life

Neuron23’s CEO talks about company building and using machine learning to develop individualized therapies